Review • Revue| Volume 44, ISSUE 12, P1279-1288, December 2022

Efficacy and Safety of Oral GnRh Antagonists in Patients With Uterine Fibroids: A Systematic Review

Published:November 08, 2022DOI:



      This review aimed to assess the efficacy and safety of GnRH antagonists in patients with symptomatic uterine fibroids.

      Data Sources

      A literature search was performed on PubMed, Web of Science, Embase, Cochrane, and using the MeSH and Emtree terms “leiomyoma” and “gonadotropin-releasing hormone.”

      Study Selection

      All clinical trials that provided efficacy and safety data in clinical terms (i.e., reduction in menstrual bleeding and discomfort, changes in the size of leiomyoma and uterine volume, etc.) were included. We excluded all preclinical studies, case reports, meta-analyses, review articles, and clinical studies irrelevant to the study question.

      Data Extraction and Synthesis

      Two authors extracted data from 9 clinical studies. The extracted data included the study's characteristics, participants' baseline characteristics, treatment drugs, efficacy measures, and toxicity.


      Among oral GnRH antagonists, relugolix, elagolix, and linzagolix were safe in patients with uterine fibroids. These drugs, alone and in combination with E2/NETA (estradiol/norethindrone acetate), showed significantly better efficacy than placebo in improving bleeding, discomfort, uterine/leiomyoma sizes, and quality of life in premenopausal patients with symptomatic uterine fibroids. However, more randomized, double-blind, multicentre clinical trials are needed to confirm these results and to see long-term benefits.



      Cette revue visait à évaluer l’efficacité et l’innocuité des antagonistes de la GnRH chez les patientes atteintes de fibromes utérins symptomatiques.

      Sources de données

      Une recherche d’articles a été effectuée dans les bases de données PubMed, Web of Science, Embase, Cochrane et à l’aide des termes MeSH et Emtree Leiomyoma et Gonadotropin-Releasing Hormone.

      Sélection des études

      Ont été inclus tous les essais cliniques donnant des données sur l’efficacité et l’innocuité (c.-à-d. réduction des saignements menstruels et de l’inconfort, changements de la taille des léiomyomes et du volume utérin, etc.). Les études précliniques, les études de cas, les méta-analyses, les revues et les études cliniques non pertinentes pour la question à l’étude ont été exclues.

      Extraction et synthese des données

      Deux auteurs ont extrait les données de 9 études cliniques. Les données extraites étaient les caractéristiques de l’étude, les caractéristiques initiales des participantes, les médicaments de traitement, les mesures de l’efficacité et la toxicité.


      Parmi les antagonistes de la GnRH oraux, le rélugolix, l’élagolix et la linzagolix étaient sûrs chez les patientes atteintes de fibromes utérins. Ces médicaments, seuls ou en association avec E2/NETA (l’estradiol-acétate de noréthindrone), ont montré une efficacité significativement supérieure à celle du placebo pour ce qui est de l’amélioration des saignements, de l’inconfort, de la taille de l’utérus ou des léiomyomes et de la qualité de vie chez les patientes non ménopausées atteintes de fibromes utérins symptomatiques. Cependant, des essais cliniques randomisés multicentriques à double insu sont nécessaires pour confirmer ces résultats et constater des bienfaits à long terme.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Obstetrics and Gynaecology Canada
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Baird D.D.
        • Dunson D.B.
        • Hill M.C.
        • et al.
        High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence.
        Am J Obstet Gynecol. 2003; 188: 100-107
        • Catherino W.H.
        • Parrott E.
        • Segars J.
        Proceedings from the national institute of child health and human development conference on the uterine fibroid research update workshop.
        Fertil Steril. 2011; 95: 9-12
        • Levens E.D.
        • Wesley R.
        • Premkumar A.
        • et al.
        Magnetic resonance imaging and transvaginal ultrasound for determining fibroid burden: implications for research and clinical care.
        Am J Obstet Gynecol. 2009; 200 (537.e1–e7)
        • Giuliani E.
        • As-Sanie S.
        • Marsh E.E.
        Epidemiology and management of uterine fibroids.
        Int J Gynaecol Obstet. 2020; 149: 3-9
        • Donnez J.
        • Dolmans M.M.
        Uterine fibroid management: from the present to the future.
        Hum Reprod Update. 2016; 22: 665-686
        • McLaren J.S.
        • Morris E.
        • Rymer J.
        Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update.
        Menopause Int. 2012; 18: 68-72
        • Taylor D.K.
        • Holthouser K.
        • Segars J.H.
        • et al.
        Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management.
        F1000Res. 2015; (4(F1000 Faculty Rev):183)
        • Agency E.M.
        Ulipristal Acetate 5 mg Medicinal product.
        (Accessed February 20, 2022.)
        • Kashani B.N.
        • Centini G.
        • Morelli S.S.
        • et al.
        Role of medical management for uterine leiomyomas.
        Best Pract Res Clin Obstet Gynaecol. 2016; 34: 85-103
        • Farris M.
        • Bastianelli C.
        • Rosato E.
        • et al.
        Uterine fibroids: an update on current and emerging medical treatment options.
        Ther Clin Risk Manag. 2019; 15: 157-178
        • Chen C.
        • Wu D.
        • Guo Z.
        • et al.
        Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.
        J Med Chem. 2008; 51: 7478-7485
        • Miwa K.
        • Hitaka T.
        • Imada T.
        • et al.
        Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor.
        J Med Chem. 2011; 54: 4998-5012
        • Chandler J.
        • Cumpston M.
        • Li T.
        • et al.
        Cochrane Handbook for Systematic Reviews of Interventions.
        Wiley, Hoboken, NJ2019
        • Liberati A.
        • Altman D.G.
        • Tetzlaff J.
        • et al.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
        BMJ. 2009; 339: b2700
        • Schardt C.
        • Adams M.B.
        • Owens T.
        • et al.
        Utilization of the PICO framework to improve searching PubMed for clinical questions.
        BMC Med Inform Decis Mak. 2007; 7: 16
        • Sterne J.A.C.
        • Savović J.
        • Page M.J.
        • et al.
        RoB 2: a revised tool for assessing risk of bias in randomised trials.
        BMJ. 2019; 366: l4898
        • Al-Hendy A.
        • Lukes A.S.
        • Poindexter 3rd, A.N.
        • et al.
        Treatment of uterine fibroid symptoms with relugolix combination therapy.
        N Engl J Med. 2021; 384: 630-642
        • Schlaff W.D.
        • Ackerman R.T.
        • Al-Hendy A.
        • et al.
        Elagolix for heavy menstrual bleeding in women with uterine fibroids.
        New Engl J Med. 2020; 382: 328-340
        • Simon J.A.
        • Bradley L.D.
        • Liu R.
        • et al.
        Up to 12 months of elagolix sustained menstrual blood loss reduction in women with uterine fibroids.
        Obstet Gynecol. 2020; 135: 7S
        • Osuga Y.
        • Enya K.
        • Kudou K.
        • et al.
        Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial.
        Obstet Gynecol. 2019; 133: 423-433
        • Osuga Y.
        • Enya K.
        • Kudou K.
        • et al.
        Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
        Fertil Steril. 2019; 112: 922-929.e2
        • Archer D.F.
        • Stewart E.A.
        • Jain R.I.
        • et al.
        Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
        Fertil Steril. 2017; 108: 152-160.e4
        • Carr B.R.
        • Stewart E.A.
        • Archer D.F.
        • et al.
        Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial.
        Obstet Gynecol. 2018; 132: 1252-1264
        • Stewart E.A.
        • Taylor H.S.
        • Taylor R.N.
        • et al.
        Efficacy and safety of linzagolix (LGX) for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids (UF): results from two phase 3 randomized clinical trials.
        Fertil Steril. 2020; 114: e522
        • Al-Hendy A.
        • Lukes A.S.
        • Poindexter A.
        • et al.
        LIBERTY: long-term extension study demonstrating one-year efficacy and safety of relugolix combination therapy in women with symptomatic uterine fibroids.
        Fertil Steril. 2020; 114: e1
        • Taylor H.
        • Bedaiwy M.
        • Lukes A.
        • et al.
        Efficacy and safety of elagolix in a subgroup of women with uterine fibroids and adenomyosis: results from a phase 2 trial.
        J Minim Invasive Gynecol. 2018; 25 (S86–S7)
        • Friedman A.J.
        • Lobel S.M.
        • Rein M.S.
        • et al.
        Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
        Am J Obstet Gynecol. 1990; 163: 1114-1119
        • Tamaya T.
        • Fujimoto J.
        • Okada H.
        Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium.
        Acta Obstet Gynecol Scand. 1985; 64: 307-309
        • Struthers R.S.
        • Nicholls A.J.
        • Grundy J.
        • et al.
        Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
        J Clin Endocrinol Metab. 2009; 94: 545-551
        • Nakata D.
        • Masaki T.
        • Tanaka A.
        • et al.
        Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice.
        Eur J Pharmacol. 2014; 723: 167-174
        • Al-Hendy A.
        • Lukes A.S.
        • Poindexter A.
        • et al.
        Treatment of symptoms of uterine fibroids with relugolix combination therapy: efficacy and safety results from the phase 3 liberty 1 clinical trial.
        Fertil Steril. 2019; 112: e434
        • Lethaby A.
        • Vollenhoven B.
        • Sowter M.
        Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
        Cochrane Database Syst Rev. 2001; 2: CD000547
        • Sohn G.S.
        • Cho S.
        • Kim Y.M.
        • et al.
        Current medical treatment of uterine fibroids.
        Obst Gynecol Sci. 2018; 61: 192-201
        • Ko S.H.
        • Kim H.S.
        Menopause-associated lipid metabolic disorders and foods beneficial for postmenopausal women.
        Nutrients. 2020; 12: 202
        • Derby C.A.
        • Crawford S.L.
        • Pasternak R.C.
        • et al.
        Lipid changes during the menopause transition in relation to age and weight: the study of women's health across the nation.
        Am J Epidemiol. 2009; 169: 1352-1361
        • Surrey E.
        • Taylor H.S.
        • Giudice L.
        • et al.
        Long-term outcomes of elagolix in women with endometriosis: results from two extension studies.
        Obstet Gynecol. 2018; 132: 147-160